FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
[ad_1]
The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.
[ad_2]
Source link